All Industries

Top Biotech Companies

3,960 Biotech companies, sorted by total funding raised.

RecursionIPO

AI-powered drug discovery and development company that uses biological and chemical datasets, mac...

Salt Lake City, United States501–1000Artificial Intelligence, Biotech
Corporate Round·$482.9M·Jul 2023
Benchling

Unlocking the power of biotech with modern software for modern science

San Francisco, United States501–1000Biotech, SaaS
Series G+·$476.5M·Nov 2021
Innovent BiologicsIPO

Developing and commercializing high-quality biologic medicines.

Suzhou, China5001–10000Biotech, Healthcare
Venture Round·$475.0M·Jan 2025
DNA Script

DNA Script develops the SYNTAX platform for enzymatic DNA synthesis, enabling labs to print high-...

Paris, France51–200Biotech, Synthetic Biology
Series C·$466.5M·Jan 2022
InvivydIPO

Biotechnology company developing antibody-based therapies against evolving viral threats includin...

Waltham, United States51–200Biotech, Healthcare
Series C·$466.0M·Apr 2021
ArvinasIPO

Clinical-stage biotechnology company developing PROTAC protein degraders for oncology and neurode...

New Haven, United States201–500Biotech, Healthcare
Private Equity·$464.9M·Nov 2023
BiofourmisAcquired

AI-driven platform delivering remote patient monitoring and in-home care for health systems, paye...

Boston, United States201–500Artificial Intelligence, Digital Health
Series D·$461.5M·Jul 2022
Nektar TherapeuticsIPO

Research-based development stage biopharmaceutical company that discovers and develops innovative...

San Francisco, United States51–200Biotech, Healthcare
Corporate Round·$460.0M·Feb 2026
Synthego

Provides CRISPR reagents, engineered nucleases, and GMP manufacturing to researchers and therapeu...

Redwood City, United States51–200Biotech, Genomics
Series E·$460.0M·Feb 2022
ImmunomedicsClosed

Biotechnology company focused on the development of antibody-drug conjugates for the treatment of...

Morris Plains, United States201–500biotechnology, oncology
Private Equity·$459.0M·May 2020
Science.xyz

Clinical-stage medical technology company developing neural-engineering implants and platforms to...

Alameda, United States51–200Biotech, Medtech
Series C·$457.0M·Mar 2026
Crinetics Pharmaceuticals, Inc.

R&D company with 6 SBIR/STTR awards from Department of Health and Human Services.

San Diego, United States11–50Biotech, Healthcare
Venture Round·$453.5M·Jan 2026
Phathom PharmaceuticalsIPO

Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing ...

Florham Park, United States201–500Biotech, GI Health
Venture Round·$450.3M·May 2023
GalectoIPO

Clinical-stage biotech developing small-molecule therapeutics targeting galectin and other mechan...

Copenhagen, Denmark11–50Biotech, Drug Development
Series C·$446.9M·Nov 2025
X4 PharmaceuticalsIPO

Clinical-stage biopharmaceutical company developing novel, oral medicines designed to treat a ran...

Boston, United States51–200Biotech, Drug Discovery
Series C·$446.8M·Oct 2025
Owkin

Owkin combines life-science and machine learning expertise to make drug development and clinical ...

San Francisco, United States201–500Artificial Intelligence, Biotech
Corporate Round·$445.2M·Jan 2023
Cue HealthClosed

Biotech company empowering personalized, proactive healthcare through at-home diagnostic testing.

San Diego, United States201–500Biotech, Healthcare
Series D·$440.0M·May 2021
Helix

Population genomics and viral surveillance company enabling health systems and public health orga...

San Mateo, United States201–500Biotech, Diagnostics
Series C·$435.0M·Jun 2021
Avalyn

Developing inhaled therapies to treat people with severe respiratory disease.

Boston, United States11–50Biotech, Healthcare
Series D·$434.5M·Jul 2025
Ollin Biosciences

Biotechnology company developing novel therapeutics.

Austin, United States11–50Biotech, Healthcare
Venture Round·$430.0M·Jun 2026
Verve TherapeuticsAcquired

Develops one-time in vivo gene-editing medicines to prevent and treat atherosclerotic cardiovascu...

Boston, United States201–500Biotech, Drug Discovery
Series C·$428.5M·Oct 2024
Areteia TherapeuticsClosed

Clinical-stage biotechnology developing an oral eosinophil-maturation inhibitor (dexpramipexole) ...

Chapel Hill, United States11–50Biotech, Life Sciences
Series A·$425.0M·Feb 2024
BioNTech

German biotech company developing mRNA-based immunotherapies and vaccines.

Mainz, Germany5001–10000Biotech, Healthcare
Series A·$425.0M·Jan 2019
Allogene TherapeuticsIPO

Clinical-stage biotechnology company developing allogeneic CAR T cell therapies for blood cancers...

South San Francisco, United States51–200Biotech, Healthcare
Series A·$420.0M·Apr 2018
Angitia Biopharmaceuticals

Clinical-stage biotech developing novel bispecific antibody therapies for musculoskeletal and bon...

Westlake Village, United States51–200Biotech, Healthcare
Series D·$420.0M·Feb 2026